A matching-adjusted indirect comparison of ELEVATE-TN versus SEQUOIA: acalabrutinib with and without obinutuzumab versus zanubrutinib in treatment-naive chronic lymphocytic leukemia

被引：0
|
作者：
Kittai, Adam
Allan, John
James, Dan
Bridge, Helen
Miranda, Miguel
Yong, Alan
Fam, Fady
Roos, Jack
Shetty, Vikram
Skarbnik, Alan
Davids, Matthew
机构：
来源：
LEUKEMIA & LYMPHOMA | 2023年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1550098
引用
收藏
页码：S82 / S83
页数：2
相关论文
共 50 条
  • [31] SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib Versus Bendamustine plus Rituximab (BR) in Patients With Treatment-Naive (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
    Kahl, Brad S.
    Giannopoulos, Krzysztof
    Jurczak, Wojciech
    Simkovic, Martin
    Shadman, Mazyar
    Osterborg, Anders
    Laurenti, Luca
    Walker, Patricia
    Opat, Stephen
    Chan, Henry
    Ciepluch, Hanna
    Greil, Richard
    Tani, Monica
    Trneny, Marek
    Brander, Danielle M.
    Flinn, Ian W.
    Grosicki, Sebastian
    Verner, Emma
    Brown, Jennifer R.
    Ghia, Paolo
    Li, Jianyong
    Tian, Tian
    Zhou, Lei
    Marimpietri, Carol
    Paik, Jason C.
    Cohen, Aileen
    Robak, Tadeusz
    Hillmen, Peter
    Tam, Constantine S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S269 - S270
  • [32] Acalabrutinib in Combination with Venetoclax and Obinutuzumab or Rituximab in Patients with Treatment-Naive or Relapsed/Refractory Chronic Lymphocytic Leukemia
    Woyach, Jennifer A.
    Blachly, James S.
    Rogers, Kerry A.
    Bhat, Seema A.
    Grever, Michael R.
    Kittai, Adam S.
    Jianfar, Mojgan
    Lozanski, Gerard
    Weiss, David M.
    Andersen, Barbara L.
    Patel, Priti
    Munugalavadla, Veerendra
    Butturini, Anna
    Xu, Yan
    Wang, Min Hui
    Byrd, John C.
    BLOOD, 2020, 136
  • [33] Safety and efficacy of acalabrutinib and obinutuzumab in treatment-naive chronic lymphocytic leukemia: a Japanese phase 1 study
    Takizawa, Jun
    Teshima, Takanori
    Ennishi, Daisuke
    Ichikawa, Satoshi
    Suzuki, Ritsuro
    Kojima, Akira
    Takahashi, Yusuke
    Hayashi, Nobuya
    Kawasumi, Hisashi
    Murayama, Kosho
    Cheung, Patricia
    Kawata, Toshio
    Izutsu, Koji
    LEUKEMIA & LYMPHOMA, 2024,
  • [34] Acalabrutinib in Combination With Venetoclax and Obinutuzumab or Rituximab in Patients With Treatment-Naive or Relapsed/Refractory Chronic Lymphocytic Leukemia
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 9 - 10
  • [35] ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL)
    Sharman, Jeff P.
    Banerji, Versha
    Fogliatto, Laura Maria
    Herishanu, Yair
    Munir, Talha
    Walewska, Renata
    Follows, George
    Karlsson, Karin
    Ghia, Paolo
    Corbett, Gillian
    Walker, Patricia
    Egyed, Miklos
    Jurczak, Wojciech
    Salles, Gilles
    Janssens, Ann
    Cymbalista, Florence
    Wierda, William G.
    Coutre, Steven
    Pagel, John M.
    Skarbnik, Alan
    Kamdar, Manali
    Woyach, Jennifer
    Izumi, Raquel
    Munugalavadla, Veerendra
    Patel, Priti
    Wang, Min Hui
    Wong, Sofia
    Byrd, John C.
    BLOOD, 2019, 134
  • [36] MATCHING-ADJUSTED INDIRECT COMPARISON OF EFFICACY AND SAFETY OF ACALABRUTINIB VERSUS IBRUTINIB IN THE TREATMENT OF RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
    Telford, C.
    Kabadi, S.
    Abhyankar, S.
    Song, J.
    Signorovitch, J.
    Zhao, J.
    Yao, Z.
    VALUE IN HEALTH, 2019, 22 : S62 - S62
  • [37] Pirtobrutinib versus venetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia: a matching-adjusted indirect comparison
    Al-Sawaf, Othman
    Jen, Min-Hua
    Hess, Lisa M.
    Zhang, Jiewen
    Goebel, Benjamin
    Pagel, John M.
    Abhyankar, Sarang
    Davids, Matthew S.
    Eyre, Toby A.
    HAEMATOLOGICA, 2024, 109 (06) : 1866 - 1873
  • [38] Adjusted indirect comparison of zanubrutinib and ibrutinib in first-line treatment of chronic lymphocytic leukemia
    Salmeron-Navas, Francisco Javier
    Barreiro-Fernandez, Ester Maria
    Fenix-Caballero, Silvia
    FARMACIA HOSPITALARIA, 2024, 48 (01) : 9 - 15
  • [39] Contribution of Obinutuzumab to Acalabrutinib Therapy in Patients with Treatment-Naive Chronic Lymphocytic Leukemia: Analysis of Survival Outcomes By Genomic Features
    Davids, Matthew S.
    Sharman, Jeff P.
    Eyre, Toby A.
    Woyach, Jennifer A.
    de Miranda, Paulo Andre P.
    Shahkarami, Mina
    Butturini, Anna
    Emeribe, Ugochinyere
    Byrd, John C.
    BLOOD, 2022, 140 : 4173 - 4175
  • [40] Contribution of obinutuzumab to acalabrutinib therapy in patients with treatment-naive chronic lymphocytic leukemia: analysis of survival outcomes by genomic features
    Schabath, R.
    Davids, M. S.
    Sharman, J. P.
    Eyre, T. A.
    Woyach, J. A.
    de Miranda, P. A. P.
    Shahkarami, M.
    Butturini, A.
    Emeribe, U.
    Byrd, J. C.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 218 - 218
12345